1、Click here or press enter for the accessibility optimised versionASH 2023 PreviewOnes to WatchClick here or press enter for the accessibility optimised versionContentsContentsForewordArcellxRegeneronGileadVertexMorphoSysClick here or press enter for the accessibility optimised versionCAR-T Safety an

2、d Sickle Cell DiseaseTwo big themes are set to dominate this year.The firstis safety.The FDAs investigation of T-cell malignanciesassociated with CAR-T products approved for bloodcancers may make these treatments less appealing.However,many patients with autoimmune diseases andcancer already accept

3、some risk of secondarymalignancies,so this isnt necessarily going to derail thewhole CAR-T space.We can expect plenty ofdiscussion of the likely impact of the news in the panelsessions and the networking gigs throughout theASH weekend.The other hot topic will be the latest data in sickle celldisease

4、,sparked by the go-ahead for Vertexs geneediting therapy in the UK.The US is expected to followwith approved very soon,but questions remain aboutthe very small number of patients who can truly benefitfrom this sophisticated but expensive therapy.Expect to hear many views on how we balance thesenew t

5、reatments with existing,more accessible,therapies and how we track the long-term risk of thesetechnologies.As ever,ASH will see the latest data reveals on CAR-Tproducts,multiple myeloma,leukaemia and more.In thiseBook,we outline five key players-Arcellx,Gilead,Regeneron,Vertex and MorphoSys-with a s

6、napshotof their pipelines,commercial outlook,and the datatheyre set to present at the conference.CAR-T Safety and Sickle CellDiseaseThe American Society of Hematology(ASH)Annual Meeting and Exposition is the lastbig clinical conference of the year.As wehead into 2024,which areas are set toattract in